Home
About Us
Information & Guidelines
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
Information For Authors
Information Editorial Board
Contact Us
FAQ
Paper Submission Guideline
Register
Login
Submit Now
Vol - 25, Issue - 8
Full-Text PDF
About the Journal
Download
[This article belongs to Volume - 25, Issue - 8]
International Medical Journal
Journal ID
:
IMJ-20-07-2020-542
Total View
:
335
Title
:
Rifaximin in hepatic encephalopathy: A review of the literature
Abstract
: Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis with a great socioeconomic impact, which impairs the quality of life of patients. Non-absorbable disaccharides and rifaximin are the most commonly used treatments along with the correction of precipitating factors. There are few randomized-controlled trials and many of the current treatment recommendations are based on clinical practice. Rifaximin should start during an episode of HE if there is no clinical improvement after 24-48 hours of non-absorbable disaccharides therapy. Rifaximin as an add-on therapy to lactulose is prudent in recurrent HE in patients who develop a new episode. Rifaximin has proven an effective treatment option for overt HE and in the prevention of recurrence
Download Info
×
Paper Access Key
Access Key
Submit
No Access Key (
Request for Download
)
Name
Email
Country
Send Request
Our Certificates
Guidelines
Information For Authors
Information Editorial Board
FAQ
Further Information
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
//